Renvela 800 (Sevelamer Carbonate Tablet) 800mg

Renvela 800mg tablets contain sevelamer carbonate, a phosphate binder used to control high phosphate levels in adults with chronic kidney disease. This non-calcium phosphate binder helps maintain balanced mineral levels. Store at 15–25°C to preserve potency and efficacy.

Strength

800mg

Pack Size

180s

Storage

15 -25ºC

Manufacturer / TM Owner

Sanofi-Aventis

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Sevelamer carbonate is primarily used to manage hyperphosphatemia, a condition where phosphate levels are too high in the blood. It works by binding dietary phosphate in the digestive tract, reducing absorption. This medication is commonly prescribed for patients undergoing dialysis or with chronic kidney disease who need phosphate control.

Side Effects

Renvela 800mg tablets may help normalize phosphate levels when taken as directed with meals. Some users report improved digestive comfort and fewer phosphate-related symptoms over time. Consistent use supports overall mineral balance in kidney disease management.

Precautions & Warnings

Keep Renvela 800mg tablets in a dry place away from moisture and direct heat. Do not crush or split tablets unless advised by a healthcare professional. If you experience persistent nausea or constipation, consult a doctor. Always follow storage instructions to maintain medication integrity.

Avoid Interactions

Sevelamer carbonate may interact with medications that require acidic environments for absorption, such as certain antibiotics or thyroid hormones. Avoid taking it with calcium supplements or vitamin D unless directed. Alcohol and high-fat meals can sometimes affect phosphate absorption, so timing with meals is important.

Frequently Asked Questions

Renvela 800mg tablets are used to control high phosphate levels in adults with chronic kidney disease, especially those on dialysis.

Store Renvela 800mg tablets at 15–25°C in a dry place, away from moisture and direct sunlight.

Some users may experience mild digestive discomfort like nausea or constipation when taking Renvela 800mg.

Renvela 800mg should be taken with meals to effectively bind dietary phosphate, but avoid high-fat meals that may affect absorption.

No, Renvela 800mg tablets require a prescription and are not available for purchase without one.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.